Stoke Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
one of the biotech analysts here at the firm. It is my pleasure to introduce our next presenting company, Stoke Therapeutics. From the company here, we have two executives. We have the Chief Executive Officer, Ian Smith. We also have Chief Patient Officer, Jason Hoitt. Ian, thank you so much. Gentlemen, thank you so much for spending time with us. Perhaps, Ian, you can maybe start us off, make some opening comments, talk about the milestones or the key things that we should be focusing on, and then we'll go into a Q&A.
Yeah, okay. Thank you, Yatin, and thank you for people that are joining us today here in person and those that may be joining us online. Stoke is a company that's focused on genetic medicines for genetic diseases. It has an approach where it upregulates protein from a healthy allele to address the underlying cause of genetic diseases. We're primarily focused in genetic epilepsies, but we also have medicines in ophthalmic areas as well, and I'm sure we'll talk about those today. The lead medicine is a medicine for Dravet syndrome, which is a disease that, unfortunately, children develop normally through potentially 18 months to two years of age, and then plateau in terms of neurodevelopment for the rest of their lives. These children suffer from severe motor seizures, as well as learning and neurocognitive disabilities.
Our medicine fortunately works to reduce those seizures that they have, but then also potentially show, based on data that we've seen, gives them gain of function to actually lift them up off that plateauing of potentially a two-year-old.
If you're a 10-year-old and you go onto our medicine, we start to add back tasks and function in terms of cognition and behavior to these children. We're in phase III study at this point in time. We'll provide you with an update today, as we did with the investors just a couple of weeks ago in our Q3 call. The study's progressing very nicely. As of a week or so ago, when we had our Q3 call, we had zero discontinuations. We've enrolled 162 patients, and as you know, Yatin, two-thirds of the patients are already through the primary endpoint of the study, which is at week 28. So, it's progressing very nicely. In terms of milestones in the next year, the next 12-24 months, we have a phase III study readout that should be in Q3 of 2027.
And if that data is supportive, a potential approval in early 2028, then obviously the launch would be within that 2028 period into a patient population that is sizable for a rare disease. And the commercial opportunity for us is significant given that we potentially have a disease-modifying medicine into this disease population. Close behind Dravet, we have a medicine that is in a phase I/II single-dose escalation study in ADOA, which is a genetic progressive loss of eyesight. And our target there is OPA1, where we look to increase the expression of OPA1 to actually give back eyesight, potentially give back eyesight into these patients that are progressively losing their eyesight and ultimately go legally blind. So company has progressed incredibly well over the last year and continues to do so, and we are looking forward to into 2027 to be a very important year.
Very good, Ian. Thank you for that. Perhaps in the beginning, we will spend some time on the disease itself and the long-term data that you have generated. So Dravet, I think, as a syndrome is beyond, let us say, seizure, right? When we talk to physician, and I think even caregiver, they also talk about the cognitive behavior burden that it possesses. So the question is, you have generated now long-term data, so what has that four-year worth of data from a long-term perspective has sort of taught you about potential to change the course of disease in these patients?
Yeah, thanks for the question, Yatin. Just for everybody's awareness, we ran phase I/II studies in these Dravet children ages two through 18, and we gave them the opportunity to, after the dose escalation studies in the phase I/II, gave them the opportunity to move into an open-label study. Approximately 90% of the patients that were in the phase I/II chose to move into the open-label study, and approximately 70%-80% of those patients are still in the OLE study four years later. So the OLE study now has been run for four years. I want to be clear that this is a chronically dosed medicine. It is an ASO, and it is dosed every four months into these children. And this is a disease where these children are suffering seizures, but also do not develop cognitive and neurodevelopment. It is stunted. What we have seen from that four-year data now of chronic dosing in these patients, and the patient numbers are still around 60 patients, we have seen this durable reduction at doses that are similar to those that we are studying in the phase III of around 80% from their baseline.
So seizure reduction around 80%, and that is durable out through four years now. So incredible data in terms of durability of response in seizures. And then from the cognition and behavioral aspects of these children, we are seeing this gain of task and function as measured by Vineland. Vineland is a measuring tool that allows you to measure receptive communication, expressive communication, interpersonal skills, personal skills. And what we have seen is this accumulation of task and function, gain of function through this four-year period.
And what I mean through the four-year period is that they have more gain of function in year two than they do year one, and more in year three than they had in year two, and more in year four than they had in year three. So we are actually in this rare position where we are running a 52-week registration study, phase III registration study, yet we have data in nearly as many patients as we are studying in the phase III that is supportive of the medicine in terms of seizure reduction and improvement of cognition and behavior. So it is a unique position to have that much data while running the phase III study.
And the other thing that we take confidence from the OLE study is all these patients, well, not all the patients, but most of the patients have been on drug a long time now, where anywhere between three and four years in the four-year OLE study. So we take away confidence on the safety profile of the drug in that we have not seen anything that would create any concern in terms of as we move forward within the phase III.
Got it. Very good. Very helpful, Ian Smith. Now let us just focus on the EMPEROR phase III study. I think you have over-enrolled and have provided some sort of color in terms of how well the translation, how many patients are continuing into the OLE. Can you maybe talk about what is the aim for this study? What would you like to show? How would you characterize a successful outcome, both on the primary endpoint and the Vineland score that you are looking at, Vineland endpoint?
Success is hitting a P-value of less than 0.05, to be honest, and that is reduction in seizures as the primary endpoint at week 28, but also hitting a P-value of less than 0.05 in the cognition and behavioral aspect of measuring via Vineland. That endpoint is one that is measured by taking a combination of different Vineland domains, measuring each domain separately. So there are four domains you measure each four separately. You actually add them together, divide by four, it gives you an average, and that is called an MC4, multicomponent four- Yeah score of Vineland.
That is the key secondary endpoint that would be important for us to achieve a P-value of less than 0.05. What that would do is it would provide us with a label to allow us to promote the medicine as a seizure reduction and cognition and behavioral benefit drug, i.e., a disease-modifying drug, promote the medicine as a disease-modifying medicine. That is the importance of getting the P-values and having this data on the label.
Got it. So perhaps on this modification in the Vineland, the way it is calculated, I mean, we have gotten some inbound from investors, particularly focus on why this modification is made and why this might be a better way to capture the disease modification in Dravet syndrome, if you can just comment on both of them.
Yeah, sure. It is a good question, frankly, and it is the most frequently asked question that we have had in probably the last three or four weeks since we put out a press release on the outcome with the FDA. So I need to help people understand that where we have come from and where we are today. The protocol in the SAP was initially agreed in terms of a hierarchical assessment of five key Vineland sub-domains. What that means in regulatory FDA speak is that you have to hit the Vineland domains in a priority and in an order.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
